Viatris VTRS Zoloft ® — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Viatris in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viatris's zoloft ® — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viatris's zoloft ® — net sales?
- Viatris (VTRS) reported zoloft ® — net sales of $72.6M in Q1 2026.
- How has Viatris's zoloft ® — net sales changed year-over-year?
- Viatris's zoloft ® — net sales increased by 20.6% year-over-year, from $60.2M to $72.6M.
- What is the long-term trend for Viatris's zoloft ® — net sales?
- Over 4 years (2021 to 2025), Viatris's zoloft ® — net sales has grown at a -2.7% compound annual growth rate (CAGR), from $284.3M to $254.9M.
- What does zoloft ® — net sales mean?
- This metric represents the total revenue generated from the sale of the Zoloft brand pharmaceutical product after accounting for returns, allowances, and discounts. It serves as a key indicator of the product's market demand, pricing power, and lifecycle stage within the company's portfolio of established medicines. Monitoring this figure helps investors assess the contribution of legacy branded assets to the company's overall top-line performance.